Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency.

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

According to the abstract, 54 patients were involved.

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.

The researchers recruited 54 consecutive hypopituitary patients with AGHD.

Among them, 31 patients who had received GHRT for more than 24 months were compared with 19 age- and sex-matched patients without GHRT.

How the Study Was Run

This is a retrospective observational study.

The researchers also analyzed the long term effect of GHRT on 14 patients diagnosed with NASH by liver biopsy.

What Was Measured

The subject headings attached to it are Case-Control Studies, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism, Liver and Non-alcoholic Fatty Liver Disease.

The authors tagged it with the keywords Adult growth hormone deficiency (AGHD), Growth hormone replacement therapy, Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH).

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 54 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.